Cargando…

Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis

BACKGROUND: Sarcopenic obesity (SO) has been indicated as a scientific and clinical priority in oncology. This meta-analysis aimed to investigate the impacts of preoperative SO on therapeutic outcomes in gastrointestinal surgical oncology. METHODS: We searched the PubMed, EMBASE, and Cochrane Librar...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Peiyu, Wang, Shaodong, Ma, Yi, Li, Haoran, Liu, Zheng, Lin, Guihu, Li, Xiao, Yang, Fan, Qiu, Mantang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355157/
https://www.ncbi.nlm.nih.gov/pubmed/35938099
http://dx.doi.org/10.3389/fnut.2022.921817
_version_ 1784763229632724992
author Wang, Peiyu
Wang, Shaodong
Ma, Yi
Li, Haoran
Liu, Zheng
Lin, Guihu
Li, Xiao
Yang, Fan
Qiu, Mantang
author_facet Wang, Peiyu
Wang, Shaodong
Ma, Yi
Li, Haoran
Liu, Zheng
Lin, Guihu
Li, Xiao
Yang, Fan
Qiu, Mantang
author_sort Wang, Peiyu
collection PubMed
description BACKGROUND: Sarcopenic obesity (SO) has been indicated as a scientific and clinical priority in oncology. This meta-analysis aimed to investigate the impacts of preoperative SO on therapeutic outcomes in gastrointestinal surgical oncology. METHODS: We searched the PubMed, EMBASE, and Cochrane Library databases through March 4th 2022 to identify cohort studies. Endpoints included postoperative complications and survival outcomes. Newcastle Ottawa Scale was used for quality assessment. Heterogeneity and publication bias were assessed. Subgroup analyses and sensitivity analyses were performed. RESULTS: Twenty-six studies (8,729 participants) with moderate to good quality were included. The pooled average age was 65.6 [95% confidence interval (CI) 63.7–67.6] years. The significant heterogeneity in SO definition and diagnosis among studies was observed. Patients with SO showed increased incidences of total complications (odds ratio 1.30, 95% CI: 1.03–1.64, P = 0.030) and major complications (Clavien-Dindo grade ≥ IIIa, odds ratio 2.15, 95% CI: 1.39–3.32, P = 0.001). SO was particularly associated with the incidence of cardiac complications, leak complications, and organ/space infection. SO was also predictive of poor overall survival (hazard ratio 1.73, 95% CI: 1.46–2.06, P < 0.001) and disease-free survival (hazard ratio 1.41, 95% CI: 1.20–1.66, P < 0.001). SO defined as sarcopenia in combination with obesity showed greater association with adverse outcomes than that defined as an increased ratio of fat mass to muscle mass. A low prevalence rate of SO (< 10%) was associated with increased significance for adverse outcomes compared to the high prevalence rate of SO (> 20%). CONCLUSION: The SO was associated with increased complications and poor survival in gastrointestinal surgical oncology. Interventions aiming at SO have potentials to promote surgery benefits for patients with gastrointestinal cancers. The heterogeneity in SO definition and diagnosis among studies should be considered when interpreting these findings. SYSTEMATIC REVIEW REGISTRATION: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=255286], identifier [CRD42021255286].
format Online
Article
Text
id pubmed-9355157
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93551572022-08-06 Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis Wang, Peiyu Wang, Shaodong Ma, Yi Li, Haoran Liu, Zheng Lin, Guihu Li, Xiao Yang, Fan Qiu, Mantang Front Nutr Nutrition BACKGROUND: Sarcopenic obesity (SO) has been indicated as a scientific and clinical priority in oncology. This meta-analysis aimed to investigate the impacts of preoperative SO on therapeutic outcomes in gastrointestinal surgical oncology. METHODS: We searched the PubMed, EMBASE, and Cochrane Library databases through March 4th 2022 to identify cohort studies. Endpoints included postoperative complications and survival outcomes. Newcastle Ottawa Scale was used for quality assessment. Heterogeneity and publication bias were assessed. Subgroup analyses and sensitivity analyses were performed. RESULTS: Twenty-six studies (8,729 participants) with moderate to good quality were included. The pooled average age was 65.6 [95% confidence interval (CI) 63.7–67.6] years. The significant heterogeneity in SO definition and diagnosis among studies was observed. Patients with SO showed increased incidences of total complications (odds ratio 1.30, 95% CI: 1.03–1.64, P = 0.030) and major complications (Clavien-Dindo grade ≥ IIIa, odds ratio 2.15, 95% CI: 1.39–3.32, P = 0.001). SO was particularly associated with the incidence of cardiac complications, leak complications, and organ/space infection. SO was also predictive of poor overall survival (hazard ratio 1.73, 95% CI: 1.46–2.06, P < 0.001) and disease-free survival (hazard ratio 1.41, 95% CI: 1.20–1.66, P < 0.001). SO defined as sarcopenia in combination with obesity showed greater association with adverse outcomes than that defined as an increased ratio of fat mass to muscle mass. A low prevalence rate of SO (< 10%) was associated with increased significance for adverse outcomes compared to the high prevalence rate of SO (> 20%). CONCLUSION: The SO was associated with increased complications and poor survival in gastrointestinal surgical oncology. Interventions aiming at SO have potentials to promote surgery benefits for patients with gastrointestinal cancers. The heterogeneity in SO definition and diagnosis among studies should be considered when interpreting these findings. SYSTEMATIC REVIEW REGISTRATION: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=255286], identifier [CRD42021255286]. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9355157/ /pubmed/35938099 http://dx.doi.org/10.3389/fnut.2022.921817 Text en Copyright © 2022 Wang, Wang, Ma, Li, Liu, Lin, Li, Yang and Qiu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Wang, Peiyu
Wang, Shaodong
Ma, Yi
Li, Haoran
Liu, Zheng
Lin, Guihu
Li, Xiao
Yang, Fan
Qiu, Mantang
Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis
title Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis
title_full Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis
title_fullStr Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis
title_full_unstemmed Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis
title_short Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis
title_sort sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: a meta-analysis
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355157/
https://www.ncbi.nlm.nih.gov/pubmed/35938099
http://dx.doi.org/10.3389/fnut.2022.921817
work_keys_str_mv AT wangpeiyu sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis
AT wangshaodong sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis
AT mayi sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis
AT lihaoran sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis
AT liuzheng sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis
AT linguihu sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis
AT lixiao sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis
AT yangfan sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis
AT qiumantang sarcopenicobesityandtherapeuticoutcomesingastrointestinalsurgicaloncologyametaanalysis